Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

Exelixis’ liver cancer drug cabozantinib meets primary end point in phase 3 trial By PBR Staff Writer
Exelixis’ liver cancer drug cabozantinib (Cabometyx) has met its primary end point in the global phase 3 Celestial trial.
Contract Research & Services > Clinical Trials > News
Pfizer’s lung cancer drug lorlatinib succeeds in phase 2 trial Pfizer says that its investigational, next-generation tyrosine kinase inhibitor lorlatinib showed clinically meaningful activity against lung tumors and brain metastases in a phase 2 trial in patients with ALK-positive and ROS1-positive advanced non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News miRagen Therapeutics reports positive clinical data of MRG-106 in patients with mycosis fungoides form of cutaneous T-cell lymphoma miRagen Therapeutics has announced new interim results from its ongoing phase 1 clinical trial evaluating the safety, efficacy and pharmacokinetics of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL).
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
Human clinical trial commences for first leprosy vaccine candidate
The Infectious Disease Research Institute (IDRI) and American Leprosy Missions have started a Phase 1 clinical trial in humans for leprosy vaccine candidate, the first vaccine developed specifically for leprosy.
Contract Research & Services > Clinical Trials > News
Ardelyx's phase 3 study of Tenapanor for IBS-C meets primary endpoint
Ardelyx has released positive results from its second Phase 3 study of tenapanor, dubbed T3MPO-2, for irritable bowel syndrome with constipation (IBS-C).
Contract Research & Services > Clinical Trials > News
Shield Therapeutics enrolls patients for phase 3 study of IDA drug Feraccru
Shield Therapeutics has completed enrollment of the Phase 3 AEGIS-CKD clinical trial of its European-marketed product, Feraccru.
Contract Research & Services > Clinical Trials > News
NanOlogy begins NanoPac’s phase 2 study to treat ovarian cancer
By PBR Staff Writer
NanOlogy has commenced the Phase 2 clinical study of intraperitoneally (IP) administered NanoPac (nanoparticle paclitaxel) to treat ovarian cancer.
Contract Research & Services > Clinical Trials > News
Bayer, Janssen halt phase III ESUS study of anticoagulant medicine Xarelto
By PBR Staff Writer
Bayer, along with its development partner Janssen Research & Development, has halted the phase III Navigate ESUS study of rivaroxaban (Xarelto), as it demonstrated comparable efficacy between treatment arms.
Contract Research & Services > Clinical Trials > News
Anthem, HealthCore, Boehringer initiate pragmatic clinical trial to study people living with COPD in real-world setting
The first patients have now enrolled in AIRWISE, the world’s largest ever pragmatic clinical trial in chronic obstructive pulmonary disease (COPD) to study how commonly prescribed medicines may reduce the occurrence of exacerbations of COPD.
Contract Research & Services > Clinical Trials > News
Zika vaccine found safe, promising in first human trial
By PBR Staff Writer
A DNA-based Zika vaccine, dubbed GLS-5700, developed by a consortium led by Inovio Pharmaceuticals and GeneOne Life Science succeeded in a phase 1 clinical trial by producing anti-Zika response in humans.
Contract Research & Services > Clinical Trials > News
Motif Bio’s iclaprim meets primary endpoint in second phase 3 ABSSI trial
By PBR Staff Writer
UK-based Motif Bio reported that its skin disorder drug iclaprim has succeeded in a second phase 3 trial in patients with acute bacterial skin and skin structure infections (ABSSSI).
Contract Research & Services > Clinical Trials > News
10,000 to be tested in world’s first trial for universal flu vaccine
By PBR Staff Writer
NHS patients are taking part in a world-first trial for a universal flu vaccine supported by the National Institute for Health Research (NIHR) and delivered by the University of Oxford in Berkshire and Oxfordshire.
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests